Local 12: Chemotherapy in recurrent ovarian cancer patients
UC researcher publishes New England Journal of Medicine study looking at outcomes
The five-year survival rate for ovarian cancer is only 36%, one of the worst cancer survival rates out there.
Finding the right treatments, however, is critical to changing that survival rate, according to Dr. Thomas Herzog, a professor at UC and gynecologic oncologist with UC Health. His team just released a study in the New England Journal of Medicine comparing those who just had chemotherapy with a recurrent cancer and those who had chemotherapy in addition to surgery when the cancer came back.
Featured photo courtesy of Unsplash.
Related Stories
UC summer program gives high school students hands-on research experience
March 18, 2026
The University of Cincinnati College of Medicine is expanding its Medical Sciences Summer Institute (MSSI) this year with a new medical informatics track.
Coding without code: How vibe coding rewrites the rules
March 17, 2026
Vibe coding allows beginners to build sophisticated web applications with zero coding skills. Discover how vibe coding can simplify workflows and drastically boost productivity.
How the University of Cincinnati co-op program is shaping the future of work at SXSW
March 17, 2026
The University of Cincinnati served as a 2026 Workplace Track sponsor at the annual South by Southwest (SXSW) Innovation Conference March 12-18 in Austin, Texas, showcasing how co-op is redesigning the future of work.